Quality systems regulating the manufacture of drugs and active pharmaceutical ingredients (APIs) have been successfully established in the European Union. These current Good Manufacturing Practices (cGMPs) guaranty the safety of pharmaceutical raw materials and products and their compliance with the quality requirements defined by international pharmacopoeias (e.g. BP, EP, JP, USP etc.).
Kirsch Pharma appreciates the new AMWHV as the transfer of Directive 2004/27/EC into German law demanding the implementation of the GMP Regulations for APIs in accordance with part II of the European GMP Guideline and ICH Q7A.
The new legislation on GMP rules for API’s in Germany reflects Kirsch Pharma’s quality philosophy regarding manufacture and release of pharmaceutical raw materials for our customers worldwide.
The implementation of the new regulation by Kirsch Pharma demands certain provisions in order to comply with the current German legislation.
1) Distinction between active ingredient and excipient regarding their suitability:
Unless not unequivocally labelled as active ingredient all pharmaceutical raw materials as provided by Kirsch Pharma are considered as pharmaceutical excipients even though supplied with multiple pharmacopoeia designations and not specifically labelled as excipient.
2) Assignment of APIs to the original manufacturer:
Active pharmaceutical ingredients not originally produced by Kirsch Pharma will be supplied with the information about the original manufacturer as already done in the past on our customer’s request.
3) Excipients supplied by Kirsch Pharma and utilized by our customers as active pharmaceutical ingredients.
In order to comply with the current pharmaceutical legislation and to be able to perform additional qualification measures, we have to know the specific requirement and purpose of use of our product. We therefore need your cooperation and ask our cus-tomers to contact us directly if applicable.
4) Non-GMP substances suitable as APIs supplied by Kirsch Pharma and utilized by our customers as active pharmaceutical ingredients:
Our product portfolio also comprises substances that come from non-GMP manufacturing processes but have been qualified according to other quality standards. Due to the fact that actually no exceptional or transitional regulation is in place regarding the use of substances not primarily produced as active pharmaceutical ingredients but which the customer may also decide to use as active ingredients, Kirsch Pharma cannot offer these substances as APIs. We therefore ask our customers not to hesi-tate to contact Kirsch Pharma in order to solve any problem regarding future supply with convenient product qualities.